Title (en)

HYPERICIN AND HYPERICUM EXTRACT: SPECIFIC T-TYPE CALCIUM CHANNEL BLOCKER, AND THEIR USE AS T-TYPE CALCIUM CHANNEL TARGETED THERAPEUTICS

Title (de)

HYPERICIN UNR HYPERICUM-EXTRAKT: SPEZIFISCHE T-TYP CALCIUMKANALBLOCKER, UND IHRE VERWENDUNG ALS T-TYP CALCIUMKANALGERICHTETE THERAPEUTIKA

Title (fr)

HYPERICINE ET EXTRAIT D'HYPERICUM: AGENTS BLOQUANT LES CANAUX DE CALCIUM DE TYPE C ET LEUR UTILISATION COMME AGENTS THERAPEUTIQUES DIRIGES CONTRE LE CANAL DE CALCIUM DE TYPE T

Publication

EP 1094712 A4 20040908 (EN)

Application

EP 99933542 A 19990709

Priority

• US 9914132 W 19990709
• US 9222798 P 19980709

Abstract (en)

[origin: WO0002455A1] Hypericin has been shown to specifically inhibit T-type calcium channel activity. Hypericum extract containing hypericin also inhibits T-type calcium channel activity. Moreover, other chemicals in Hypericum extract showed a synergistic effect to hypericin. In view of this, hypericin or hypericin-containing Hypericum extract can be used as T-channel blockers. Hypericum extract, extract of other species of the Hypericum genus, extract of other plants containing hypericin, hypericin derivatives, hypericin analogs, such as pseudohypericin, and other Hypericum extract constituents can be used as therapeutics targeted at T-type calcium channels for treatment of diseases associated with T-channel abnormality. Methods for administering hypericin and Hypericum extract are disclosed.

IPC 1-7

A01N 65/00; A01N 35/00; A01N 29/00; C07C 17/00; C07C 19/08; C07C 22/00

IPC 8 full level

A61K 36/18 (2006.01); A61K 31/12 (2006.01); A61K 31/19 (2006.01); A61K 31/215 (2006.01); A61P 3/08 (2006.01); A61P 3/10 (2006.01); A61P 7/00 (2006.01); A61P 9/00 (2006.01); A61P 9/04 (2006.01); A61P 9/06 (2006.01); A61P 9/12 (2006.01); A61P 25/06 (2006.01); A61P 25/08 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 43/00 (2006.01); C07C 49/657 (2006.01); C07C 49/687 (2006.01); C07C 49/703 (2006.01); C07C 50/36 (2006.01); C07C 65/36 (2006.01); C07C 69/00 (2006.01); C07C 69/007 (2006.01); C07C 69/017 (2006.01); C07C 69/95 (2006.01); C07C 309/44 (2006.01); C07C 309/57 (2006.01)

CPC (source: EP KR)

A61K 36/38 (2013.01 - KR); A61P 3/08 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 7/00 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/04 (2017.12 - EP); A61P 9/06 (2017.12 - EP); A61P 9/12 (2017.12 - EP); A61P 15/06 (2017.12 - EP); A61P 25/06 (2017.12 - EP); A61P 25/08 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07C 50/36 (2013.01 - EP); C07C 69/95 (2013.01 - EP); C07C 2603/54 (2017.04 - EP)

Citation (search report)

• [X] WO 9827970 A2 19980702 - CA NAT RESEARCH COUNCIL [CA], et al
• [X] WO 9630012 A1 19961003 - DEFEUDIS FRANCIS V [US]
• [X] WO 8903213 A1 19890420 - BILAS ANDOR [AT]
• [PX] DE 19700788 A1 19980716 - RUEPP MICHAEL O [DE]
• [X] US 5514714 A 19960507 - MERUELO DANIEL [US], et al
• [X] WO 9427952 A1 19941208 - YEDA RES & DEV [IL], et al
• See references of WO 0002455A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0002455 A1 20000120; AU 4958199 A 20000201; CA 2336781 A1 20000120; CA 2336781 C 20101214; CN 1308492 A 20010815; EP 1094712 A1 20010502; EP 1094712 A4 20040908; JP 2002520260 A 20020709; KR 20010071822 A 20010731

DOCDB simple family (application)

US 9914132 W 19990709; AU 4958199 A 19990709; CA 2336781 A 19990709; CN 99808429 A 19990709; EP 99933542 A 19990709; JP 2000558725 A 19990709; KR 20017000390 A 20010109